Curocell Inc. (KOSDAQ:372320)

South Korea flag South Korea · Delayed Price · Currency is KRW
33,850
+200 (0.59%)
Last updated: Jul 18, 2025
8.84%
Market Cap505.62B
Revenue (ttm)n/a
Net Income (ttm)-35.47B
Shares Out14.32M
EPS (ttm)-2,511.78
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume737,236
Average Volume64,378
Open34,500
Previous Close33,650
Day's Range33,200 - 34,700
52-Week Range19,390 - 36,000
Betan/a
RSI70.17
Earnings DateAug 13, 2025

About Curocell

Curocell Inc. develops CAR-T cell therapy for the treatment of cancer. It focuses on the development of CD19 CAR-T for the treatment of lymphoma; and BCMA CAR-T for the treatment of multiple myeloma. The company was incorporated in 2016 and is based in Daejeon, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Employees 136
Stock Exchange KOSDAQ
Ticker Symbol 372320
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.